Consensus Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Real-time Estimate Cboe BZX Other stock markets 03:09:16 2024-05-23 pm EDT			5-day change	1st Jan Change
2.545 ^USD	-4.32%		-16.61%	-21.81%

May. 21	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	MT
May. 16	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	MT

Evolution of the average Target Price on Allogene Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e44ab73e2c1.yp4_Cb9mHrU4YBdgj4odQtqN0rfAaYiejZr-59LkQKU.h8xZPMcsL_pdWHRY6PtHOJ7Puf6NUMf9xMPHv6COKdHz8GdZ8yJ6xnUXeA~81ab12490d22a4f3298af0a3d8f3081d

Analyst Recommendations on Allogene Therapeutics, Inc.

Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	May. 21	MT
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	May. 16	MT
Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	May. 14	MT
B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	May. 14	MT
Allogene Therapeutics Prices $110 Million Offering	May. 13	MT
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	Jan. 19	MT
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	Jan. 05	MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	Jan. 05	MT
Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target	Dec. 08	MT
HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating	Nov. 15	MT
JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating	23-09-25	MT
Truist Securities Lowers Allogene Therapeutics' Price Target to $18 From $20, Maintains Buy Rating	23-07-11	MT
RBC Lowers Allogene Therapeutics' Price Target to $12 From $15, Keeps Outperform Rating	23-07-07	MT
JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outperform Rating	23-05-05	MT
Stifel Nicolaus Adjusts Allogene Therapeutics Price Target to $7.50 From $8, Maintains Hold Rating	23-05-04	MT
RBC Capital Adjusts Allogene Therapeutics Price Target to $15 From $22, Maintains Outperform - Speculative Risk Rating	23-04-06	MT
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $23 From $29, Maintains Buy Rating	23-04-04	MT
Bernstein Initiates Allogene Therapeutics at Market Perform With $6 Price Target	23-03-21	MT
JMP Securities Adjusts Price Target on Allogene Therapeutics to $19 From $23, Maintains Market Outperform Rating	23-03-02	MT
Oppenheimer Adjusts Allogene Therapeutics Price Target to $28 From $32, Maintains Outperform Rating	23-03-01	MT
B. Riley Lowers Allogene Therapeutics' Price Target to $15 From $18 Due to Setback in Initiating Potentially Pivotal ALLO-715 Trial, Keeps Buy Rating	23-03-01	MT
Goldman Sachs Adjusts Allogene Therapeutics Price Target to $31 From $35, Maintains Buy Rating	23-03-01	MT
RBC Cuts Price Target on Allogene Therapeutics to $22 From $32 Amid BCMA Delay, Maintains Outperform, Speculative Risk	23-03-01	MT
JPMorgan Upgrades Allogene Therapeutics to Overweight From Neutral, Adjusts Price Target to $11 From $20	23-01-24	MT
Baird Upgrades Allogene Therapeutics to Outperform From Neutral, Price Target at $12	23-01-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.66 USD

Average target price

11.34 USD

Spread / Average Target

+326.38%

High Price Target

35 USD

Spread / Highest target

+1,215.79%

Low Price Target

4.5 USD

Spread / Lowest Target

+69.17%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Allogene Therapeutics, Inc.

Oppenheimer
HC Wainwright
Stifel Nicolaus
B. Riley
JMP Securities
Citigroup
JPMorgan Chase
Truist Securities
RBC Capital Markets
Bernstein
Goldman Sachs
Baird
EF Hutton
BofA Securities
Raymond James
Guggenheim
Cowen
SMBC Nikko
Roth Capital Partners
Jefferies & Co.

Ratings for Allogene Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar